Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours
Abstract Purpose microRNA-371a-3p (M371) is considered a highly sensitive and specific serum biomarker of testicular germ cell tumours (GCTs). However, little is known about the expression of M371 in nontesticular malignancies (NTMs), so far. As knowledge about the expression of the marker in other...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-025-06101-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572016850370560 |
|---|---|
| author | Gazanfer Belge Markus Klemke Bendix Hansen Cansu Dumlupinar Aylin Igde Dirk Arnold Hans Salwender Christian Wülfing Armin Soave Klaus-Peter Dieckmann |
| author_facet | Gazanfer Belge Markus Klemke Bendix Hansen Cansu Dumlupinar Aylin Igde Dirk Arnold Hans Salwender Christian Wülfing Armin Soave Klaus-Peter Dieckmann |
| author_sort | Gazanfer Belge |
| collection | DOAJ |
| description | Abstract Purpose microRNA-371a-3p (M371) is considered a highly sensitive and specific serum biomarker of testicular germ cell tumours (GCTs). However, little is known about the expression of M371 in nontesticular malignancies (NTMs), so far. As knowledge about the expression of the marker in other malignancies is a prerequisite for the clinical application of the test we aimed to explore the M371 expression in other cancers. Methods M371 serum levels were measured in 137 patients with NTM of 12 different neoplastic entities using the IVDR-certified M371-Test for quantitative real-time PCR. Median M371 serum levels and percentages of M371 level elevations were calculated for the entire NTM group and for entity-specific subgroups. The results were compared with GCT patients (n = 20) and with tumour-free male controls (n = 20) using descriptive statistical methods. Results Eight patients with NTMs had M371 serum level elevations, corresponding to a false-positive rate (FPR) of 5.84% (95% confidence intervals (CIs) 2.55–11.18%). Expression rates in GCTs and controls were 100% and zero, respectively. Thus, the specificity of the M371-Test for GCT is 94.90% (95% CI 90.21–97.77%) when all NTMs and tumour-free controls are considered. Remarkably, three out of 5 patients with multiple myeloma had elevated M371 levels. Conclusion The false-positive rate of the M371-Test in other malignancies than GCT is very low, and almost identical with that in healthy males, corresponding to a high specificity of 94.9% for detection of GCT. The surprising finding of M371 elevations in patients with multiple myeloma needs further investigation. |
| format | Article |
| id | doaj-art-91d6149ad1044f869855b4d0cb89379c |
| institution | Kabale University |
| issn | 1432-1335 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Journal of Cancer Research and Clinical Oncology |
| spelling | doaj-art-91d6149ad1044f869855b4d0cb89379c2025-02-02T12:07:12ZengSpringerJournal of Cancer Research and Clinical Oncology1432-13352025-01-0115121710.1007/s00432-025-06101-4Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumoursGazanfer Belge0Markus Klemke1Bendix Hansen2Cansu Dumlupinar3Aylin Igde4Dirk Arnold5Hans Salwender6Christian Wülfing7Armin Soave8Klaus-Peter Dieckmann9Department of Tumour Genetics, Faculty of Biology and Chemistry, University of BremenDepartment of Tumour Genetics, Faculty of Biology and Chemistry, University of BremenDepartment of Urology, Asklepios Tumorzentrum Hamburg, AK AltonaDepartment of Tumour Genetics, Faculty of Biology and Chemistry, University of BremenDepartment of Tumour Genetics, Faculty of Biology and Chemistry, University of BremenDepartment of Oncology, Asklepios Tumorzentrum Hamburg, AK AltonaDepartment of Oncology, Asklepios Tumorzentrum Hamburg, AK AltonaDepartment of Urology, Asklepios Tumorzentrum Hamburg, AK AltonaDepartment of Urology, University Medical Center Hamburg-EppendorfDepartment of Urology, Asklepios Tumorzentrum Hamburg, AK AltonaAbstract Purpose microRNA-371a-3p (M371) is considered a highly sensitive and specific serum biomarker of testicular germ cell tumours (GCTs). However, little is known about the expression of M371 in nontesticular malignancies (NTMs), so far. As knowledge about the expression of the marker in other malignancies is a prerequisite for the clinical application of the test we aimed to explore the M371 expression in other cancers. Methods M371 serum levels were measured in 137 patients with NTM of 12 different neoplastic entities using the IVDR-certified M371-Test for quantitative real-time PCR. Median M371 serum levels and percentages of M371 level elevations were calculated for the entire NTM group and for entity-specific subgroups. The results were compared with GCT patients (n = 20) and with tumour-free male controls (n = 20) using descriptive statistical methods. Results Eight patients with NTMs had M371 serum level elevations, corresponding to a false-positive rate (FPR) of 5.84% (95% confidence intervals (CIs) 2.55–11.18%). Expression rates in GCTs and controls were 100% and zero, respectively. Thus, the specificity of the M371-Test for GCT is 94.90% (95% CI 90.21–97.77%) when all NTMs and tumour-free controls are considered. Remarkably, three out of 5 patients with multiple myeloma had elevated M371 levels. Conclusion The false-positive rate of the M371-Test in other malignancies than GCT is very low, and almost identical with that in healthy males, corresponding to a high specificity of 94.9% for detection of GCT. The surprising finding of M371 elevations in patients with multiple myeloma needs further investigation.https://doi.org/10.1007/s00432-025-06101-4Testicular germ cell tumourBiomarkermicroRNA-371a-3pMultiple myelomaChromosome 19, test specificity |
| spellingShingle | Gazanfer Belge Markus Klemke Bendix Hansen Cansu Dumlupinar Aylin Igde Dirk Arnold Hans Salwender Christian Wülfing Armin Soave Klaus-Peter Dieckmann Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours Journal of Cancer Research and Clinical Oncology Testicular germ cell tumour Biomarker microRNA-371a-3p Multiple myeloma Chromosome 19, test specificity |
| title | Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours |
| title_full | Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours |
| title_fullStr | Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours |
| title_full_unstemmed | Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours |
| title_short | Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours |
| title_sort | biomarker microrna 371a 3p expression in malignancies other than germ cell tumours |
| topic | Testicular germ cell tumour Biomarker microRNA-371a-3p Multiple myeloma Chromosome 19, test specificity |
| url | https://doi.org/10.1007/s00432-025-06101-4 |
| work_keys_str_mv | AT gazanferbelge biomarkermicrorna371a3pexpressioninmalignanciesotherthangermcelltumours AT markusklemke biomarkermicrorna371a3pexpressioninmalignanciesotherthangermcelltumours AT bendixhansen biomarkermicrorna371a3pexpressioninmalignanciesotherthangermcelltumours AT cansudumlupinar biomarkermicrorna371a3pexpressioninmalignanciesotherthangermcelltumours AT aylinigde biomarkermicrorna371a3pexpressioninmalignanciesotherthangermcelltumours AT dirkarnold biomarkermicrorna371a3pexpressioninmalignanciesotherthangermcelltumours AT hanssalwender biomarkermicrorna371a3pexpressioninmalignanciesotherthangermcelltumours AT christianwulfing biomarkermicrorna371a3pexpressioninmalignanciesotherthangermcelltumours AT arminsoave biomarkermicrorna371a3pexpressioninmalignanciesotherthangermcelltumours AT klauspeterdieckmann biomarkermicrorna371a3pexpressioninmalignanciesotherthangermcelltumours |